|
목적 : To investigate a clinical outcome after more than 4 years for polypoidal choroidal vasculopathy (PCV) treated with anti-vascular endothelial growth factor (VEGF) therapy and to investigate the factors predictive of long-term visual outcomes.
방법 : This retrospective study included 31 eyes with PCV treated with anti-VEGF therapy (either ranibizumab or bevacizumab, or both), and were followed-up for 4 years or longer. The best-corrected visual acuity (BCVA) at baseline was compared with that measured at 12, 24, and 36 months, and at the final follow-up. Factors associated with final visual acuity were also analyzed.
결과 : The follow-up period was 53.0±4.3 months. The patients were treated with an average of 8.8±3.0 intravitreal anti-VEGF injections. BCVA at diagnosis at 12,24,and 36months, and at final follow-up was 0.52±0.35,0.46±0.36,0.57±0.45,0.76±0.56,0.83±0.60. BCVA at 12,24 and 36months was not different from the baseline value. However, BCVA at the final follow-up had deteriorated compared to the baseline value(P=0.034). Among the included eyes, 48.4% experienced deterioration of visual acuit and 51.6% showed stable vision. BCVA at 12months was most associated with visual acuity at final follow-up
결론 : Although the long-term treatment outcome of PCV is generally unfavorable, stable vision can be achieved in approximately half of the patients. Visual acuity at 12 months after the initial treatment is predictive of long-term visual outcomes.
|